Sekar Kathiresan - Jan 8, 2025 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Stock symbol
VERV
Transactions as of
Jan 8, 2025
Transactions value $
$0
Form type
4
Date filed
1/10/2025, 09:00 AM
Previous filing
Dec 4, 2024
Next filing
Jan 30, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Award $0 +488K $0.00 488K Jan 8, 2025 Common Stock 488K $6.01 Direct F1
transaction VERV Restricted Stock Units Award $0 +120K $0.00 120K Jan 8, 2025 Common Stock 120K Direct F2, F3
transaction VERV Stock Option (right to buy) Award $0 +150K $0.00 150K Jan 8, 2025 Common Stock 150K $6.01 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on January 8, 2025. 25% of the shares underlying the option will vest on January 8, 2026, and the remainder are scheduled to vest in equal monthly installments thereafter until January 8, 2029.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock.
F3 On January 8, 2025, the reporting person was granted restricted stock units, vesting in three equal annual installments, beginning on April 1, 2026, and the remaining two installments vesting on April 1, 2027 and April 1, 2028.
F4 The option was granted on January 8, 2025. 100% of the shares underlying the option will vest immediately if and when the last quoted trading price per share of the Company's common stock on the Nasdaq Global Select Market is equal to or greater than $20.00 for at least 15 consecutive trading days on or prior to the second anniversary of the grant date.